1. Home
  2. PERI vs CLLS Comparison

PERI vs CLLS Comparison

Compare PERI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Perion Network Ltd.

PERI

Perion Network Ltd.

HOLD

Current Price

$9.51

Market Cap

412.5M

Sector

Technology

ML Signal

HOLD

Logo Cellectis S.A.

CLLS

Cellectis S.A.

HOLD

Current Price

$4.41

Market Cap

476.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PERI
CLLS
Founded
1999
1999
Country
Israel
France
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
412.5M
476.5M
IPO Year
2006
2007

Fundamental Metrics

Financial Performance
Metric
PERI
CLLS
Price
$9.51
$4.41
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$14.75
$8.50
AVG Volume (30 Days)
265.1K
114.5K
Earning Date
02-18-2026
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$432,361,000.00
$82,551,000.00
Revenue This Year
N/A
$32.58
Revenue Next Year
$8.59
$20.68
P/E Ratio
N/A
N/A
Revenue Growth
N/A
129.04
52 Week Low
$7.00
$1.10
52 Week High
$11.79
$5.48

Technical Indicators

Market Signals
Indicator
PERI
CLLS
Relative Strength Index (RSI) 43.25 46.07
Support Level $9.30 $4.62
Resistance Level $9.79 $4.97
Average True Range (ATR) 0.24 0.25
MACD -0.05 -0.04
Stochastic Oscillator 25.00 41.18

Price Performance

Historical Comparison
PERI
CLLS

About PERI Perion Network Ltd.

Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: